What are the key takeaways for Procept Biorobotics Corp ($PRCT)?

Revenue growth remains strong at 20.2% YoY, driven by sustained adoption of the Aquablation therapy platform and increasing utilization of disposable handpieces. Company continues to operate with significant cash burn, reporting negative free cash flow of $41.0 million in Q1 2026 as investment in commercial expansion and R&D persists. Gross margins remain resilient at 64.9%, validating the scalability of the recurring revenue model despite inflationary pressures on manufacturing costs.

Procept Biorobotics Corp (PRCT) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Based on March 31, 2026

Latest Report Overview for PROCEPT BioRobotics Corporation ($PRCT)

Procept Biorobotics Corp (PRCT) reported for the quarterly period ended March 31, 2026 (Issuer fiscal Q1 FY2026) revenue of $83.1 million (+20.2% YoY) with a net loss of $31.6 million and diluted EPS of -$0.56. The company maintained a robust gross margin of 64.9%, reflecting strong unit economics for its Aquablation robotic surgical platform, even as it continues to prioritize rapid market penetration and physician adoption of its minimally invasive BPH treatment.

Key Takeaways

1.Revenue growth remains strong at 20.2% YoY, driven by sustained adoption of the Aquablation therapy platform and increasing utilization of disposable handpieces.
2.Company continues to operate with significant cash burn, reporting negative free cash flow of $41.0 million in Q1 2026 as investment in commercial expansion and R&D persists.
3.Gross margins remain resilient at 64.9%, validating the scalability of the recurring revenue model despite inflationary pressures on manufacturing costs.
4.R&D expenditure reached $21.5 million in Q1 2026, highlighting the company's commitment to innovating the robotic surgical suite and expanding clinical applications for Aquablation.
5.Operating losses persist with an operating margin of -39.2%, reflecting the heavy SG&A load required to support the ongoing build-out of the U.S. and international sales force.
6.The balance sheet remains liquid with $245.6 million in cash, providing a sufficient runway for continued commercial scaling at the current burn rate.

What They Do

Procept Biorobotics Corp is a surgical robotics company that develops and markets the Hydrus system, which utilizes its proprietary Aquablation therapy to treat benign prostatic hyperplasia (BPH). Aquablation is a minimally invasive surgical procedure that uses a heat-free waterjet to remove prostate tissue, providing a surgeon-controlled, robotic-assisted solution that aims to balance symptom relief with the preservation of sexual function for patients suffering from BPH. The company serves the urology market, primarily targeting hospitals and ambulatory surgery centers where surgeons perform prostate surgeries. Their business model focuses on placing the capital-intensive robotic systems into these facilities and then generating recurring revenue from the sale of single-use, disposable handpieces utilized in every procedure. This strategy ensures long-term revenue visibility as the installed base of systems grows across domestic and international markets.

How They Make Money

The company recognizes revenue primarily through the sale of the Hydrus robotic surgical system and the recurring sale of single-use, proprietary disposable handpieces. The revenue split leans heavily on the recurring component, as every Aquablation procedure requires the use of one handpiece, providing a predictable, volume-driven revenue stream that scales with the installed base. Revenue growth is driven by the number of active robotic systems in the field (the installed base) and the average utilization rate per system by urologists. As the company acquires new hospital customers and expands the clinical acceptance of Aquablation, both the capital sales and the high-margin disposable sales contribute to top-line expansion. Key metrics include the number of new system placements and the average quarterly utilization per account.

Competitive Position

Procept Biorobotics competes in the crowded BPH treatment market, facing competition from traditional surgical procedures such as Transurethral Resection of the Prostate (TURP), as well as other minimally invasive surgical therapies (MIST) and laser-based solutions (e.g., HoLEP). Competitors range from large, diversified medical device companies with established market presence to smaller, niche players in the MIST segment. The company differentiates itself through the unique 'heat-free' nature of the Aquablation waterjet, which aims to reduce the side effects common in thermal-based procedures like TURP or laser treatments. While the robotic nature of the platform offers precision and standardization, the high cost of the system compared to manual tools remains a hurdle. Financial trends indicate strong market penetration, though the company's negative profitability relative to larger, diversified competitors highlights the ongoing costs of commercial scaling and the high intensity of capital required to displace established standards of care.

Business Strategy & Moat

Procept Biorobotics employs a strategy focused on displacing the 'gold standard' TURP procedure by positioning Aquablation as a superior, robotic-assisted alternative. The moat is primarily based on the intangible asset of its proprietary technology (heat-free waterjet) and the high switching costs associated with training surgeons on the specific Hydrus robotic platform. Once a surgical team is trained and a hospital has integrated the robot into its workflow, the friction of switching to a competitor's system is high. Capital allocation is heavily weighted toward R&D and commercial infrastructure, such as sales force expansion and medical education programs. This growth-at-all-costs strategy is designed to achieve economies of scale and improve operating leverage over time. The durability of this moat depends on clinical data proving long-term outcomes and the ability to maintain the 'razor-razorblade' flywheel as the installed base matures and utilization increases per unit.

Industry Outlook

The urology market, particularly the BPH treatment space, is undergoing a shift toward minimally invasive, robotic-assisted technologies as patients and providers seek alternatives to traditional surgery that offer better quality-of-life outcomes. Demographic trends, specifically the aging global population, continue to drive an increase in the prevalence of BPH, providing a sustained tailwind for the industry. However, the industry faces headwinds from hospital capital budget constraints and the high cost of robotic surgical platforms, which can lengthen sales cycles. Regulatory environments remain stringent, requiring robust clinical evidence for new therapy adoption. The competitive landscape is becoming increasingly crowded with both established large-cap device players and nimble robotic startups, making market share acquisition a primary driver of success.

Growth Drivers

•Expansion of the installed base of Hydrus robotic surgical systems in both new and existing hospital accounts.
•Increasing adoption and utilization rates of the Aquablation handpieces within the current installed base.
•Continued clinical education and training programs for urologists to increase the pool of surgeons capable of performing the procedure.
•Geographic expansion into international markets, leveraging regulatory approvals to drive global procedure volume.
•Innovation in the robotic software and handpiece design to improve workflow efficiency and patient outcomes.

Recent Developments

•Maintained a high pace of R&D investment, with $21.5 million spent in Q1 2026 to enhance the Hydrus robotic platform.
•Achieved 20.2% YoY revenue growth in Q1 2026, demonstrating continued market uptake of the Aquablation procedure.
•Continued commercial build-out with a focus on increasing the penetration of the U.S. urology market.
•Maintained strong liquidity position with $245.6 million in cash to support ongoing operational scaling.

Catalysts

•Positive updates or data readouts from ongoing clinical trials validating the long-term efficacy of Aquablation.
•FDA clearances for new product iterations or software upgrades to the Hydrus platform.
•Strategic partnerships with major hospital networks that could significantly increase system placement velocity.
•Quarterly earnings reports demonstrating an inflection in operating leverage or narrowing of net losses.
•Potential expansion of reimbursement coverage by major payors, which could accelerate patient demand.

RPO & Key Performance Indicators

•Revenue grew 20.2% YoY in Q1 2026, reflecting the company's ongoing success in scaling procedure volumes.
•Gross margin remained high at 64.9%, underscoring the strong recurring revenue contribution from disposable handpiece sales.

Strengths

•Proprietary heat-free waterjet technology provides a clear clinical differentiator from thermal-based surgical competitors.
•High gross margin profile (64.9%) indicates strong unit economics for the recurring disposable revenue stream.
•Established 'razor-razorblade' business model builds a defensible installed base of robotic systems.
•Proven ability to maintain consistent revenue growth and strong adoption rates in a competitive urology market.
•Liquid balance sheet with $245.6 million in cash provides a multi-year runway for commercial scaling and R&D.

AI Benefits & Opportunities

•Potential for AI-driven image guidance and tissue recognition to improve the precision of the waterjet, potentially increasing the efficiency and safety of the Aquablation procedure for surgeons.

Risks & Concerns for PROCEPT BioRobotics Corporation ($PRCT)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for PROCEPT BioRobotics Corporation (PRCT, filings period ending March 31, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Jun 8, 2026.

Peers of PROCEPT BioRobotics Corporation (PRCT)